The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.04.30.20086397: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: The investigation was based on pre-existing samples; approval was obtained from the local ethical committee. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Sera for aPL testing, collected 24h before death and frozen at −20°C, were available only for thirty-five patients that were enrolled for the study (26 male and 9 female, ratio 2.88:1; age range 57y-92y, mean and median age 73y). Table 2: Resources
Antibodies Sentences Resources Laboratory testing: IgA, IgG and IgM anti cardiolipin antibodies (ACA) and anti β2 glycoprotein 1 (β2GP1) antibodies were tested on the BioFlash® platform (Inova Diagnostics, … SciScore for 10.1101/2020.04.30.20086397: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: The investigation was based on pre-existing samples; approval was obtained from the local ethical committee. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Sera for aPL testing, collected 24h before death and frozen at −20°C, were available only for thirty-five patients that were enrolled for the study (26 male and 9 female, ratio 2.88:1; age range 57y-92y, mean and median age 73y). Table 2: Resources
Antibodies Sentences Resources Laboratory testing: IgA, IgG and IgM anti cardiolipin antibodies (ACA) and anti β2 glycoprotein 1 (β2GP1) antibodies were tested on the BioFlash® platform (Inova Diagnostics, San Diego, CA, USA) with chemiluminescence methods; to assess positive result the manufacturer cut off 20 CU (Chemiluminescence Units) was used. IgA, IgGsuggested: Noneanti cardiolipinsuggested: Noneanti β2 glycoprotein 1 (β2GP1)suggested: NoneIgG and IgM anti phosphatidylserine/prothrombin (PS/PT) antibodies were measured with a commercial ELISA kit on QUANTA-Lyser® 3000 (Inova Diagnostics, San Diego, CA, USA), using the manufacturer cut off (30 units). anti phosphatidylserine/prothrombin (PS/PT)suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
